Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Dermatology | Endocrinology | Family Medicine | Geriatrics | Gastroenterology | Gynecology | Infections | AIDS | Internal Medicine | Allergy | Critical Care | Emergency Medicine | Nephrology | Neurology | Oncology | Ophthalmology | Orthopedics | ENT | Pathology | Pediatrics | Psychiatry | Pulmonology | Radiology | Rheumatology | Surgery | Anesthesiology & Pain | Urology | Institutional

Back to Journal Articles

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Last Updated: December 15, 2017.

In order to meet the 2017 Medicare and CHIP Reauthorization Act participation reporting deadline and avoid a Medicare payment penalty in 2019, physicians must report on at least one patient and one measure by Dec. 31, and submit to Medicare no later than Feb. 28, 2018, according to a report from the American Medical Association.

FRIDAY, Dec. 15, 2017 (HealthDay News) -- In order to meet the 2017 Medicare and CHIP Reauthorization Act (MACRA) participation reporting deadline and avoid a Medicare payment penalty in 2019, physicians must report on at least one patient and one measure by Dec. 31, and submit to Medicare no later than Feb. 28, 2018, according to a report from the American Medical Association (AMA).

In order to ease the process for small practices, an online resource center has been established by the AMA, which includes step-by-step instructions and a video.

For a specific practice, a quality measure can be selected for reporting that makes sense based on the patient population or procedures performed most often. Support for selecting and reporting on appropriate measures to satisfy requirements can be accessed for those who are part of a practice with 15 or fewer clinicians.

"Stay tuned for an overview of the 2018 Quality Payment Program rule and resources to help you successfully navigate the program next year," according to the report.

More Information


Previous: Nerve Injury ID’d After High-Intensity Focused Ultrasound Next: Ulixertinib Is Active in Patients With Advanced Solid Tumors

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: